Suzhou Highfine Biotech Co (SZSE:301393) ROCE %: 6.17% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301393 Suzhou Highfine Biotech Co Ltd SZSE:301393
91 GF Score
Price ¥61.32
GF Value ¥71.95
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Suzhou Highfine Biotech Co ROCE %?

Suzhou Highfine Biotech Co SZSE:301393 -6.28% 91 ROCE % is 6.17% as of Mar. 2026. GuruFocus rates SZSE:301393 with a GF Score™ of 91/100 and a GF Value™ of ¥71.95 (Modestly Undervalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Suzhou Highfine Biotech Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.17%.

Suzhou Highfine Biotech Co  (SZSE:301393) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Suzhou Highfine Biotech Co ROCE % Related Terms

Suzhou Highfine Biotech Co ROCE % Historical Data

* Premium members only.

The historical data trend for Suzhou Highfine Biotech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Highfine Biotech Co ROCE % Chart

Suzhou Highfine Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.38 31.27 8.30 6.88 5.54

Suzhou Highfine Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.03 8.05 4.63 2.62 6.17
SZSE:301393
91GF Score
Suzhou Highfine Biotech Co Ltd SZSE:301393
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Highfine Biotech Co ROCE % Calculation

Suzhou Highfine Biotech Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=129.968/( ( (2349.619 - 71.163) + (2654.41 - 238.869) )/ 2 )
=129.968/( (2278.456+2415.541)/ 2 )
=129.968/2346.9985
=5.54 %

Suzhou Highfine Biotech Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=151.128/( ( (2654.41 - 238.869) + (2812.404 - 325.271) )/ 2 )
=151.128/( ( 2415.541 + 2487.133 )/ 2 )
=151.128/2451.337
=6.17 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.17% mean?
Suzhou Highfine Biotech Co (SZSE:301393) has a ROCE % of 6.17% as of Mar. 2026.
Is Suzhou Highfine Biotech Co's ROCE % too high?
Suzhou Highfine Biotech Co's current ROCE % is 6.17%. The Drug Manufacturers industry median ROCE % is 7.17. Suzhou Highfine Biotech Co's value of 6.17% is 13.9% below this industry median. Overall, Suzhou Highfine Biotech Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Highfine Biotech Co's ROCE % compare to ZTS?
Suzhou Highfine Biotech Co's ROCE % of 6.17% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.17. Suzhou Highfine Biotech Co's value of 6.17% is 13.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.17, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Highfine Biotech Co's current ROCE % of 6.17% is 13.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Highfine Biotech Co's current ROCE % is 6.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Highfine Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co (SZSE:301393) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥71.95, compared to a current price of ¥61.32 — trading 14.8% below its estimated fair value. The current ROCE % is 6.17% and 13.9% below the Drug Manufacturers industry median of 7.17. Suzhou Highfine Biotech Co's overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Suzhou Highfine Biotech Co (SZSE:301393), the current ROCE % is 6.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Highfine Biotech Co (SZSE:301393) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Highfine Biotech Co stock appears to be undervalued. The current stock price of ¥61.32 is trading 14.8% below its estimated GF Value™ of ¥71.95. GuruFocus considers Suzhou Highfine Biotech Co to be Modestly Undervalued.

Key valuation signals for SZSE:301393:

  • ROCE %: 6.17%
  • GF Value™: ¥71.95 vs. price of ¥61.32 (14.8% below fair value)
  • GF Score™: 91/100 with 8 warning signs
  • Industry Position: 13.9% below the Drug Manufacturers median

No single metric tells the full story. See the SZSE:301393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Suzhou Highfine Biotech Co Business Description

Address No. 32 Hongxi Road, F-12 Standard Factory Building, High-tech Zone, Jiangsu Province, Suzhou, CHN, 215151
Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.
91GF Score

Get the complete analysis for SZSE:301393

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥61.32
Price
¥71.95
GF Value